Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00339937
Status:
COMPLETED
Last Update Posted:
2024-03-22
First Post:
2006-06-19
Brief Title:
Studies of Human Herpesvirus 8 and Kaposis Sarcoma in Sicily
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Studies of Human Herpesvirus 8 and Kaposis Sarcoma in Sicily
Status:
COMPLETED
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A series of studies will be conducted in Sicily by a collaborative team from the US National Cancer Institute and the University of Palermo to better understand the prevalence and risk factors for the newly discovered human herpes virus 8 HHV8 and Kaposi s sarcoma KS which may be a consequence of HHV8 infection There are four short-term projects
1 To determine HHV8 seroprevalence in extant unlinked sera from informative groups including homosexual men persons with sexually transmitted diseases and in general population groups particularly the elderly In addition HHV8 prevalence and other serological studies may be determined among other adults particularly those who may be recruited for future studies and those likely to enhance understanding of HHV8 serology
2 To identify a pediatric syndrome that might be associated with HHV8 infection HHV8 seroprevalence will be determined in sera from hospitalized children with a wide range of clinical conditions
3 To determine HHV8 seroprevalence in various regions of Italy and by HLA Class II groups that have been linked to increased HLA-DR5 or decreased HLA-DR3 risk of KS using extant unlinked sera and data from volunteer bone marrow donors
4 To conduct a case control study that will identify risk factors for KS among persons who are infected with HHV8 and who manifest anti-HHV8 latent antibodies
The results of these projects will be summarized for publication in the medical and scientific literature and for the design and prioritization of related projects in the future
1 To determine HHV8 seroprevalence in extant unlinked sera from informative groups including homosexual men persons with sexually transmitted diseases and in general population groups particularly the elderly In addition HHV8 prevalence and other serological studies may be determined among other adults particularly those who may be recruited for future studies and those likely to enhance understanding of HHV8 serology
2 To identify a pediatric syndrome that might be associated with HHV8 infection HHV8 seroprevalence will be determined in sera from hospitalized children with a wide range of clinical conditions
3 To determine HHV8 seroprevalence in various regions of Italy and by HLA Class II groups that have been linked to increased HLA-DR5 or decreased HLA-DR3 risk of KS using extant unlinked sera and data from volunteer bone marrow donors
4 To conduct a case control study that will identify risk factors for KS among persons who are infected with HHV8 and who manifest anti-HHV8 latent antibodies
The results of these projects will be summarized for publication in the medical and scientific literature and for the design and prioritization of related projects in the future
Detailed Description:
A series of studies will be conducted in Sicily by a collaborative team from the US National Cancer Institute and the University of Palermo to better understand the prevalence and risk factors for the newly discovered human herpes virus 8 HHV8 and Kaposi s sarcoma KS which may be a consequence of HHV8 infection There are four short-term projects
1 To determine HHV8 seroprevalence in extant unlinked sera from informative groups including homosexual men persons with sexually transmitted diseases and in general population groups particularly the elderly In addition HHV8 prevalence and other serological studies may be determined among other adults particularly those who may be recruited for future studies and those likely to enhance understanding of HHV8 serology
2 To identify a pediatric syndrome that might be associated with HHV8 infection HHV8 seroprevalence will be determined in sera from hospitalized children with a wide range of clinical conditions
3 To determine HHV8 seroprevalence in various regions of Italy and by HLA Class II groups that have been linked to increased HLA-DR5 or decreased HLA-DR3 risk of KS using extant unlinked sera and data from volunteer bone marrow donors
4 To conduct a case control study that will identify risk factors for KS among persons who are infected with HHV8 and who manifest anti-HHV8 latent antibodies
The results of these projects will be summarized for publication in the medical and scientific literature and for the design and prioritization of related projects in the future
1 To determine HHV8 seroprevalence in extant unlinked sera from informative groups including homosexual men persons with sexually transmitted diseases and in general population groups particularly the elderly In addition HHV8 prevalence and other serological studies may be determined among other adults particularly those who may be recruited for future studies and those likely to enhance understanding of HHV8 serology
2 To identify a pediatric syndrome that might be associated with HHV8 infection HHV8 seroprevalence will be determined in sera from hospitalized children with a wide range of clinical conditions
3 To determine HHV8 seroprevalence in various regions of Italy and by HLA Class II groups that have been linked to increased HLA-DR5 or decreased HLA-DR3 risk of KS using extant unlinked sera and data from volunteer bone marrow donors
4 To conduct a case control study that will identify risk factors for KS among persons who are infected with HHV8 and who manifest anti-HHV8 latent antibodies
The results of these projects will be summarized for publication in the medical and scientific literature and for the design and prioritization of related projects in the future
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| OH98-C-N035 | None | None | None |